Zydus, MSN Launch First Generic Adempas (Riociguat) in US
x
Zydus Lifesciences and MSN Laboratories introduce the first generic version of Adempas (Riociguat) in the US market, approved by USFDA for CTEPH and PAH.

Key Points
- Zydus Lifesciences and MSN Laboratories launched the first generic Adempas (Riociguat) in the US market.
- The generic Riociguat tablets, developed by MSN, received USFDA approval and are available in all five strengths.
- Riociguat is indicated for treating chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH).
- This launch represents a significant milestone for Zydus's US business and showcases MSN's R&D and manufacturing capabilities.
- Global sales of the original Adempas were approximately USD 850 million in 2025.
The launch covers Riociguat tablets in all five strengths: 0.5 mg, 1 mg, 1.5 mg, 2 mg and 2.5 mg. The product was developed and manufactured by MSN Laboratories and has received approval from the US Food and Drug Administration (USFDA) as a generic equivalent of Adempas tablets, according to the filing on Monday evening.
Riociguat is a soluble guanylate cyclase (sGC) stimulator indicated for the treatment of adults with persistent or recurrent chronic thromboembolic pulmonary hypertension (CTEPH) after surgical treatment, or inoperable CTEPH. It is also indicated for adults with pulmonary arterial hypertension (PAH) to improve exercise capacity, functional class and delay clinical worsening.
Sharvil Patel, managing director of Zydus Lifesciences, said being the "first to market with generic Riociguat represents a milestone for the company's US business and reflects the strength of its complex-generics pipeline and execution capabilities".
MSN Reddy, founder and CMD of MSN Laboratories, noted that bringing the first generic of the technically-demanding molecule to the US demonstrates the depth of MSN's integrated API and formulation R&D, alongside its manufacturing scale.
According to the Bayer's Annual Report 2025 cited in the filing, global sales of Adempas were approximately USD 850 million in 2025.
You May Like To Read
TODAY'S MOST TRADED COMPANIES
- Company Name
- Price
- Volume
- Vodafone-Idea
- 12.58 ( -3.08)
- 28565437
- Rajnish-Wellness
- 0.46 (+ 17.95)
- 16011560
- String-Metaverse
- 7.15 (+ 4.99)
- 14219836
- PC-Jeweller
- 15.57 ( -2.38)
- 11334515
- NHC-Foods
- 1.72 (+ 4.88)
- 11279785






